Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity
- Cancer Cell. 2024 Dec 23:S1535-6108(24)00476-8. doi: 10.1016/j.ccell.2024.12.001.
- 1. Genome Institute of Singapore, Agency for Science, Technology, and Research (A(∗)STAR), 60 Biopolis Street, Singapore.
- 2. Department of Oncology, Odense University Hospital and Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
- 3. Singapore Phenome Center, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- 4. Institute of Molecular and Cellular Biology, A(∗)STAR, Biopolis, Singapore.
- 5. The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- 6. Institute of Molecular and Cellular Biology, A(∗)STAR, Biopolis, Singapore; Department of General Surgery, Tan Tock Seng Hospital and Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- 7. Genome Institute of Singapore, Agency for Science, Technology, and Research (A(∗)STAR), 60 Biopolis Street, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore. Electronic address: [email protected].
Successful immunotherapy relies on both intratumoral and systemic immunity, which is yet to be achieved for most patients with Cancer. Here, we identify P4HA1, encoding prolyl 4-hydroxylase 1, as a crucial regulator of CD8+ T cell differentiation strongly upregulated in tumor-draining lymph nodes (TDLNs) and hypoxic tumor microenvironment. P4HA1 accumulates in mitochondria, disrupting the tricarboxylic acid (TCA) cycle through aberrant α-ketoglutarate and succinate metabolism, promoting mitochondria unfitness and exhaustion while suppressing progenitor expansion. Targeting P4HA1 enhances both adoptive and endogenous TCF1+ CD8+ T progenitor expansion while mitigating the development of exhaustion in the tumor, TDLN, and blood, enabling a notable and durable systemic anti-cancer immunity. We propose that P4HA1 induction in CD8+ T cells in Cancer orchestrates an immune-escape program, offering a T cell-directed target for system immunotherapy in solid tumors.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
target: HIF/HIF Prolyl-HydroxylaseResearch Areas: Cancer